Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Affiliations

¹ Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain. FCERVAN@clinic.cat.
² Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, SA, Australia.
³ University Hospital Sveti Ivan Rislki, Sofia, Bulgaria.
⁴ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology "Seràgnoli", Bologna, Italy.
⁵ Department of Hematology, V.A. Baranov Republican Hospital, Petrozavodsk, Russian Federation.
⁶ CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
⁷ Hematology Service, ZNA Stuivenberg, Antwerp, Belgium.
⁸ Department of Internal Medicine I, Division of Hematology and Hemostaseology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
⁹ Juntendo University School of Medicine, Tokyo, Japan.
¹⁰ St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
¹¹ University of Insubria, Varese, Italy.
¹² Novartis Pharma, East Hanover, NJ, USA.
¹³ Novartis Healthcare Pvt. Ltd, Hyderabad, India.
¹⁴ Novartis Pharma AG, Basel, Switzerland.
¹⁵ University Hospital Halle, Halle (Saale), Germany.

Published Erratum

Francisco Cervantes et al. Leukemia. 2021 Dec.

. 2021 Dec;35(12):3626.

doi: 10.1038/s41375-021-01396-x.

¹ Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain. FCERVAN@clinic.cat.
² Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, SA, Australia.
³ University Hospital Sveti Ivan Rislki, Sofia, Bulgaria.
⁴ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology "Seràgnoli", Bologna, Italy.
⁵ Department of Hematology, V.A. Baranov Republican Hospital, Petrozavodsk, Russian Federation.
⁶ CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
⁷ Hematology Service, ZNA Stuivenberg, Antwerp, Belgium.
⁸ Department of Internal Medicine I, Division of Hematology and Hemostaseology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
⁹ Juntendo University School of Medicine, Tokyo, Japan.
¹⁰ St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
¹¹ University of Insubria, Varese, Italy.
¹² Novartis Pharma, East Hanover, NJ, USA.
¹³ Novartis Healthcare Pvt. Ltd, Hyderabad, India.
¹⁴ Novartis Pharma AG, Basel, Switzerland.
¹⁵ University Hospital Halle, Halle (Saale), Germany.

No abstract available

Erratum for

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, Zachee P, Gisslinger H, Komatsu N, Foltz L, Mannelli F, Passamonti F, Gilotti G, Sadek I, Tiwari R, Zor E, Al-Ali HK. Cervantes F, et al. Leukemia. 2021 Dec;35(12):3455-3465. doi: 10.1038/s41375-021-01261-x. Epub 2021 May 20. Leukemia. 2021. PMID: 34017073 Free PMC article. Clinical Trial.